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Radiotherapy (RT) and interferon-alfa-2b (IFN α-2b) have individually been used for adjuvant therapy stage III melanoma with
high-risk pathologic features. We hypothesized that concurrent adjuvant RT and IFN α-2b may decrease the risk of regional
recurrence following surgery with acceptable toxicity. A prospective multicenter phase I/II study was conducted to evaluate
hypofractionated RT with concurrent IFN. Induction IFN α-2b, 20 MU/m2 /d, was administered IV ×5 consecutive days every
week for 4 weeks. Next, RT 30 Gy in 5 fractions was given with concurrent IFN α-2b, 10 MU/m2 SQ 3 times per week on days
alternating with RT. Subsequent maintenance therapy consisted of adjuvant IFN α-2b, 10 MU/m2 SQ 3 times per week to a total
of 1 year. To fully evaluate patterns of failure, long-term follow-up was conducted for up to 10 years. A total of 29 consenting
patients were enrolled between August 1997 and March 2000. The maximum (worst) grade of acute nonhematologic toxicity
during concurrent RT/IFN α-2b (and up to 2 weeks post RT) was grade 3 skin toxicity noted in 2 patients (9%). Late eﬀects
were limited. Probability of regional control was 78% (95% CI: 55%–90%) at 12 months. The median follow-up (range) was 80
(51–106) months among ten survivors (43%). The median overall survival was 34.5 months while the median failure-free survival
was 19.9 months. Postoperative concurrent hypofractionated RT with IFN α-2b for advanced stage III melanoma appears to be
associated with acceptable toxicity and may provide reasonable in-field control in patients at high risk of regional failure.

1. Introduction
Results with early stage melanoma have been generally good
with high rates of local control and survival [1]. However,
some patients with advanced primaries and/or nodal disease

have not fared as well with surgery alone [2]. Despite wide
excisions of the primary and aggressive dissections of the
aﬀected nodal basins, some patients with high-risk disease
suﬀer unacceptable rates of local, regional, and distant
failure [3]. Data from multiple institutions suggest that
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Table 1: Baseline characteristics (n = 23).

Table 1: Continued.
n (%)

n (%)
Sex
M
F
Race
White
Hispanic
Staging
Missing
1
2
3
5
Initial ECOG performance status (PS)
Missing
0
1
End of treatment ECOG PS
Missing
0
1
2
ECOG PS change (end versus baseline)
Missing
Better
Same
Worse
Number of eligibility items qualified∗
1
2
3
Qualified for criterion (1)
Yes
No
Qualified for criterion (2)
Yes
No
Qualified for criterion (3)
Yes
No
Qualified for criterion (4)
Yes
No
Ulceration of primary
Yes
No
Unknown
Primary site
Ant trunk
H/N

13 (56.5)
10 (43.5)

Pos trunk

4 (17.4)

Upper ext

4 (17.4)

Unknown

6 (26.1)

Primary tumor thickness
22 (95.7)
1 (4.3)
4 (17.4)
1 (4.3)
5 (21.7)
7 (30.4)
6 (26.1)
2 (8.7)
14 (60.9)
7 (30.4)

Unknown
Breslow ≤.75 Clark II

8 (34.8)

Breslow .76–1.5 Clark III

5 (21.7)

Breslow 1.51–4.0 Clark IV

7 (30.4)

Breslow >4.0 Clark V or satellite

1 (4.3)

Nodal site
Axilla

5 (21.7)
1 (4.3)
6 (26.1)
11 (47.8)
12 (52.2)
9 (39.1)
2 (8.7)
10 (43.5)
13 (56.5)
10 (43.5)
13 (56.5)
15 (65.2)
8 (34.8)
1 (4.3)
22 (95.7)
8 (34.8)
12 (52.2)
3 (13.0)
6 (26.1)
3 (13.0)

16 (69.6)

Groin

4 (17.4)

Neck

3 (13.0)

Number of positive nodes
Missing
0–3

3 (13.0)
3 (13.0)
16 (69.6)
1 (4.3)

2 (8.7)

1 (4.3)
13 (56.5)

4–10

4 (17.4)

>10

5 (21.7)

Nodal involvement
Missing

1 (4.3)

No regional LN
1 regional station, node(s) mobile and
diameter 3 cm

1 (4.3)

1 lymph node station, diameter >3 cm or fixed
∗

7 (30.4)
14 (60.9)

See Section 2.1.

a significant number of patients with palpable lymphadenopathy will recur in the dissected basin [4]. Most
of these patients will go on to die of disseminated disease
but often suﬀer with symptomatic regional disease until
death. Prevention of local and regional failure could significantly improve the quality of life for these patients.
In the late 1990s, the introduction of interferon alfa-2b
(IFN α-2b) changed the management of patients with highrisk disease. Kirkwood et al. reported a phase III randomized
trial of adjuvant postoperative IFN α-2b which demonstrated
a substantial survival advantage in patients with nodal
involvement (overall survival was improved from 2.8 to 3.8
years) [5]. This was the first trial to show a significant benefit
from adjuvant systemic therapy and in 1997 stimulated
our group to open the long-term study presented here.
In the meantime, the data from two subsequent Eastern
Cooperative Oncology Group (ECOG) randomized trials
have suggested that while adjuvant IFN α-2b has biologic
activity with a significant increase in disease-free survival
rates, improvement in overall survival rates have not been as
robust [6, 7].
The role of radiotherapy (RT) in the curative management of melanoma has also been controversial. Initial pilot
data from multiple institutions had suggested that postoperative treatment with RT in high-risk patients could
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substantially reduce the local regional recurrence rate in stage
III melanoma [8, 9]. Indeed, postoperative RT has been
employed in various fractionation schemes, including 48 Gy
in 20 fractions 5 days per week and 30 Gy in 5 fractions
over 2-1/2 weeks (total dose 3000 cGy). RT is usually
begun approximately 3–6 weeks after surgery once wounds
are suﬃciently healed. Recent phase III randomized data
investigate the eﬃcacy of adjuvant RT in stage III melanoma
patients randomly assigned to RT (n = 109) with 48 Gy in
20 fractions, or observation (n = 109) [10]. With a median
follow-up of 27 months, the local disease relapse rate for RT
and observation was 18% and 31%, respectively, (P = 0.041).
The median survival time for radiotherapy and observation
was 2.6 years and 3.9 years (P = 0.14). There were no
diﬀerences in toxicity between lymph node fields irradiated;
no patients suﬀered from grade four toxicities.
The suggestion of potential benefit of RT and IFN α2b in similar high-risk patients raised the question of how
best to integrate these treatments in the postoperative setting.
Indeed, concurrent integration of IFN α-2b immunotherapy
with RT would avoid a delay of one of these modalities if
given sequentially. In particular, a potential delay of IFN α2b for 6–8 weeks to allow recovery from surgery and RT may
reduce the eﬀectiveness of this systemic agent.
Information is lacking describing RT given concurrently
with IFN α-2b in patients with advanced melanoma. Thus,
the purpose of this study was to (1) evaluate the acute and
late toxicity of post-operative hypofractionated RT given
concurrently with IFN α-2b to patients with extensive nodal
involvement, (2) evaluate the eﬀectiveness preventing regional
recurrence of RT given concurrently with IFN α-2b in such
patients, and (3) provide feasibility and toxicity data for a
potential subsequent randomized trial to determine the
overall value of this intervention.

2. Methods
This work was approved by the Institutional Review Board
at the University of South Florida/H. Lee Moﬃtt Cancer
Institute. This is a prospective multi-center phase I/II study
conducted to evaluate the acute and long term toxicity and
eﬃcacy of hypofractionated RT with concurrent IFN α-2b.
Centers that enrolled patients included H. Lee Moﬃtt Cancer
Center, Tampa, Florida, and the Sylvester Comprehensive
Cancer Center, University of Miami, Miami, Florida.
2.1. Patient Selection. Patient inclusion criteria included
stage III nodal disease involving the axilla, neck, or groin
characterized as “advanced” based on one or more of the
following characteristics: (1) four or more positive nodes,
(2) a single node ≥ 4 cm, (3) extracapsular disease involving
>10% of capsule circumference, or (4) soft tissue deposits in
a nodal basin after previous lymphadenectomy. In addition,
patients had to have all gross disease completely resected, no
distant metastases present, no contraindications to radiation
therapy, ECOG performance status 0-1, and life expectancy
>6 months. Recurrent stage III disease was eligible for the
study.
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Table 2: (a) Number of patients experiencing high grade (Gr
3-4) interferon-related hematologic toxicity during any phase of
therapy (n = 23). (b) Number of patients with high grade (Gr 34) interferon-related non-hematologic toxicity reported during any
phase of therapy (n = 23).
(a)

Hematologic
Leukopenia
Thrombocytopenia
Lymphocytopenia
Leukopenia w/fever

Gr 3

Gr 4

7
1
4
2

2
0
7
0

Gr 3

Gr 4

0

1

7
1
2
1

0
0
0
0

1
1
1
2
1
4

0
0
0
0
0
0

2
4
1

0
0
0

4
1
1

0
0
0

2
1
2

0
0
0

1

0

1

0

(b)

Renal
Renal failure
Gastrointestinal
Elevated LFTs
Vomiting
Nausea
Gallstones
Neurologic
Ataxia
Dizziness
TIA
Pain
Anxiety
Depression
Constitutional
Weight loss
Fatigue
Chills and fever
Skin
Rash
Pruritis
Erythema
Ocular
Cotton wool
Ulcerated
Other ocular toxicity
Cardiac
Chest pain
Pulmonary
Shortness of breath

2.2. Surgical Oncology Considerations. Definitive surgery
included wide excision of the primary and complete lymphadenectomy prior to entry into the study. Wide excision
with a minimum 1 cm margin surrounding the primary
lesion or biopsy scar was required for entry onto this
protocol. Excisions included skin and all subcutaneous tissue

4
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Table 3: Worst acute toxicity at 2 weeks post concurrent RT (n =
23).
Skin

Mucosa

14
7
2
0
23

2
1
0
0
3

RTOG
Acute toxicity grade
1
2
3
4
Total

Table 4: Number of patients experiencing high-grade (Gr 3-4) late
toxicity (n = 11).
Toxicity
Skin
Subcutaneous fibrosis
Joint
Lymphedema
Brachial plexopathy
∗

Gr 3

Gr 4

0
0
0
0
0

1∗
0
0
0
1∗

One patient same arm.

down to the muscular fascia. Fascia was included at the
discretion of the operating surgeon. Closure of the defect was
via primary closure, split thickness skin graft, or rotation flap
at the discretion of the surgeon.
For regional lymphadenectomy, all patients underwent
one of the following lymphadenectomies: (1) head and neck
lesions (to yield a minimum of 15 nodes), face, ear, and
anterior scalp: parotidectomy plus modified radical neck or
radical neck dissection, posterior scalp: modified radical or
radical neck dissection plus suboccipital nodes; (2) upper
extremity (to yield a minimum of 10 nodes), axillary node
dissection to include at least 10 nodes taken from level I
and II, with level III nodes dissected if they were clinically
involved and the pectoralis minor muscle was divided or
sacrificed at the surgeon’s discretion; and (3) lower extremity
(to yield a minimum of 5 nodes); superficial inguinal node
dissection was required with a deep inguinal node dissection
at the discretion of the surgeon.
2.3. Medical Oncology Considerations. Induction IFN α-2b,
20 MU/m2 /d, was administered intravenous × 5 consecutive
days out of 7 (Monday-Friday) every week for 4 weeks. Next,
RT consisting of 30 Gy/5 fractions (6 Gy per fraction twice-aweek on Tuesdays and Thursdays) was given with concurrent
IFN α-2b, 10 MU/m2 SQ 3 times per week (Monday,
Wesnesday, Friday) on days alternating with RT. Finally,
patients underwent consolidation/maintenance therapy with
adjuvant IFN α-2b, 10 MU/m2 SQ 3 times per week for the
remainder of 1 year.
Patients received their first injection of IFN α-2b within
3 business days of study entry. Actual weight was used when
calculating body surface area. Corticosteroids and other

immunosuppressive medications were contraindicated because of immune suppressive eﬀects. Patients who were
deemed competent to self-administer the subcutaneous
maintenance doses of IFN α-2b did so following the first 4
weeks of treatment. Dose modification criteria required the
holding of treatment until return to institution’s normal limits or patient’s baseline. A 33% reduction of dosage occurred
after first treatment interruption and a 66% reduction (of
the original dose) after the second treatment interruption
for toxicity. This was a permanent reduction. A patient who
required a third dose modification was removed from
treatment. Dose reescalation was not attempted following
resolution of toxicity that required dose interruption or
attenuation.
2.4. Radiation Oncology Considerations. RT commenced
after 4 weeks of high-dose intravenous IFN α-2b therapy.
Therapy alternated days with IFN α-2b (RT on Tuesday
and Thursday with IFN α-2b on Monday, Wednesday, and
Friday) to a total of 30 Gy in five fractions in 2-1/2 weeks.
With respect to treatment planning, treatment was given
with electrons whenever feasible. The electron energy was
appropriate for the depth of the tumor and surgical bed.
Photons were used in selected cases, for example, opposed or
10 degree oblique parallel-opposed axillary fields, or mixed
beam to the inguinal area. CT-based treatment planning was
used to limit the volume of normal tissue in-field. Field
borders were generally confined to the dissected nodal bed
with approximately 2-3 cm margins. There was no intent to
treat large elective volumes of undissected tissue (i.e., supraclavicular fossa or pelvis). Bolus was used to prevent under
dosage to tumor bed when photons and low-energy electrons
(≤6–9 MeV) were used. Tissue heterogeneity corrections for
lung were used. Isodose distributions were performed at
multiple levels, generally every 3–5 cm. Inhomogeneity did
not exceed a 5% hot spot or a 10% cold spot across the target
volume. This allowed for a maximum 15% point gradient
across the target volume. For treatment of groin or axilla,
dose was calculated to the D max anteriorly which often
results in dose to the deep axilla which was 5–8% less than
the D max dose. The junction between the abutting fields
was moved 1 cm after the 2nd and 4th treatments to prevent
dose inhomogeneity and thus minimize the risk of fibrosis.
Avoidance of critical structures was undertaken, and the
maximum permissible dose to the spinal cord was 24 Gy and
30 Gy to the brachial plexus or femoral nerve.
2.5. Follow-Up. To establish the presence of local recurrence
follow-up continued for up to 10 years following treatment.
Patients were seen monthly during interferon therapy, then
every 3 months for 1 year, every 6 months up to the end of
year 5, and then annually thereafter.
2.6. Statistical Considerations. The study was designed primarily to evaluate in a preliminary fashion the toxicity and
eﬀectiveness of postoperative hypofractionated radiotherapy
given concurrently with interferon α-2b to patients with
advanced stage III melanoma, that is, those with extensive
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Table 5: Worst late toxicity post concurrent RT/IFN (n = 11).

RTOG Acute Grade
1
2
3
4
Total

Skin atrophy
5
1
0
1
7

Fibrosis
2
3
0
0
5

Table 6: Patterns of failure among all evaluable patients (n = 23).

NED overall
In-field failure only
In-field + distant
Out-field failure only
Out-field + distant
Distant failure only
Unknown status
Regional control
Regional recurrence
TOTAL

Number
7
3
1
0
0
11
1
18
5
23

%
30.4
13.0
4.3
0
0
47.8
4.3
78.3
21.7
100

Joint motion
3
3
0
0
6

Lymphedema
2
1
0
0
3

Neuritis
0
1
0
1
2

time were also reported. In the case of TRF, the competing
risks issue due to death was also considered and alternative
methodology was used to take that into consideration.
Nonetheless, the Kaplan-Meier approach and competing
risks approach yielded very similar results, mostly due to
the fact that there was only one competing event, that is,
death, prevented regional failure, the event of interest, from
happening prior to the last occurrence of regional failure
in this study. Therefore the results using the competing
risks approach were omitted from this report. The statistical
analyses were performed using the SAS statistical software
(version 9.1; SAS Institute Inc., Cary, North Carolina).

3. Results
nodal involvement, in preventing regional recurrence. Sites
of nodal disease were stratified according to location: neck,
axilla, or groin. Fifteen treated cases were the planned accrual
goal for each of these 3 cohorts. A total of 50 cases enrolled
would account for an approximate 10% loss to follow-up
rate.
Kaplan-Meier estimates of the regional failure rates
at desired time points were calculated along with 95%
confidence intervals. With one year of postaccrual follow-up
and approximately 50 eligible cases accrued over 2.75 years,
the standard error for the two-year estimate would be 0.05 if
that estimate was 0.1 and 0.07 if it was 0.2. An estimate and
95% confidence interval for the toxicity rate would also be
calculated when appropriate. If that rate was 20% or less, the
width of the confidence interval would not exceed 22%.
This study also stipulated that the trial would be flagged
for early termination if four or more of the first fifteen
patients experience a grade 3 or greater acute or late toxicity.
The probability of this was 83% if the toxicity rate was 35%
and 6% if the toxicity rate was 10%. A total of 29 consenting
patients were registered to this trial.
Time to regional failure (TRF) was calculated from the
start of treatment to the date of regional failure. Overall
survival (OS) was calculated from the start of treatment to
the date of death. Similarly, the failure-free survival (FFS)
was defined as time from the start of treatment to the date
of death or (distant or regional) failure, whichever occured
first. All these time-to-event endpoints were censored at the
last follow-up time, if no relevant event(s) had happened by
that date. The Kaplan-Meier method was used for analysis of
these endpoints. Whenever feasible, both the point estimate
and its 95% confidence interval (CI) of the median event

A total of 29 consenting patients were enrolled between
August 1997 and March 2000. Six patients did not receive RT
(1 ineligible, 1 for technical reasons, 1 withdrew consent, 3
due to high-dose induction IFN α-2b toxicity). Twenty-three
of 29 patients (80%) received full therapy. Radiation therapy
was directed to the axillary node basin in 16, the groin in
4, and the neck in 3 patients. Due to small numbers of the
groin and neck patients, all data analyses were done pooling
all patients together. Demographic baseline data with respect
to the patients are seen in Table 1.
The number of patients experiencing high-grade (Gr 3-4)
IFN α-2b-related hematologic and nonhematologic toxicity
reported during any phase of therapy is seen in Table 2(a)
and Table 2(b), respectively. The maximum (worst) grade of
acute radiation toxicity during concurrent RT/IFN α-2b (and
up to 2 weeks post RT) was grade 3 skin toxicity noted in 2
patients (9%, Table 3).
With respect to late toxicity, no patient experienced
a grade 3 toxicity (Tables 4 and 5). Only one patient
developed a grade 4 toxicity. This occurred in a 59-yearold man with known herniated disc disease who developed
a brachial plexopathy resulting in partial disability of the
limb. It occurred following 3 cycles of bio-chemotherapy
for recurrence in the axilla. Indeed, he developed diﬃculty
raising the left arm above 60 degrees with numbness and
tingling in the ulnar distribution and contracture of his palm
and fingers. There were minimal grade 1 and 2 late radiation
toxicities following concurrent RT/IFN α-2b including skin
telangiectasia, subcutaneous fibrosis, limitation in joint
motion, and lymphedema (Table 4).
With respect to eﬀectiveness, the regional recurrence rate
was 22% (95% CI: 55%–90%) at 12 months (Table 6). The
median follow-up (range) was 80 (51–106) months among
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0.8

0.8

Failure-free survival probability

Regional control probability

6

0.6

0.4

0.2

0

0.6

0.4

0.2

0
0

24

48

72

96

120

0

Time (months)

24

48

72

96

120

Time to failure or death (months)

Figure 1: Kaplan-Meier curve and pointwise confidence intervals
for local regional control (n = 23): 5 (22%) local regional failures.

Figure 3: Kaplan-Meier curve and pointwise confidence intervals
for disease-free/failure-free survival (n = 23): 16 (70%) distant or
local regional failures or deaths; median (95% CI) FFS = 19.9 (7.7,
78.0) months.

1

4. Discussion

Overall survival probability

0.8

0.6

0.4

0.2

0
0

24

48

72

96

120

Time to death (months)

Figure 2: Kaplan-Meier curve and pointwise confidence intervals
for overall survival (n = 23): 13 (57%) deaths; median OS = 34.5
months.

ten survivors (43%); they were last seen alive at 51, 51, 66,
69, 82, 93, 95, 103, 113, and 117 months, respectively. The
Kaplan-Meier curve and its pointwise confidence intervals
for local regional control are seen in Figure 1 while the
Kaplan-Meier curves and their pointwise confidence intervals for overall survival and failure-free survival are seen in
Figures 2 and 3, respectively. The median overall survival was
34.5 months while the median failure-free survival was 19.9
months (including either distant or regional failure or death
as events). Table 7 lists estimated OS or FFS probabilities at
various time points of interest along with corresponding 95%
CIs.

Adjuvant therapy is widely used in melanoma cases because
recurrence of disease following surgical extirpation can be
diﬃcult to treat and usually results in the patient’s death
[5, 8]. Decisions regarding adjuvant therapy are based on
features of the primary melanoma and status of the sentinel
nodes. The mainstay for adjuvant therapy for stage III
high-risk melanoma remains interferon therapy for systemic
and local benefits, and adjuvant radiation for local control
[5, 8].
IFN α-2b is the only US Food and Drug Administration(FDA-) approved adjuvant regimen for patients with stage
IIB and stage III melanoma and is considered standard of
care for these patients in the United States. The Eastern
Cooperative Oncology Group (ECOG) trial E1684 was the
first randomized, placebo-controlled study of high-dose IFN
α-2b (HDI) in 287 patients with stage IIb (n = 31)
or stage III melanoma [5]. At initial publication after a
median follow-up time of 6.9 years, relapse-free survival
(RFS) increased from 1.0 to 1.7 years, and overall survival
(OS) increased from 2.8 to 3.8 years, both of which were
statistically significant [5]. Updated results after initiation of
our study with a very long median follow-up of 12.6 years
showed the RFS benefit to have been maintained, but the
statistical significance of the survival benefit had been lost
[19]. ECOG trial E1690 accrued 642 patients to a 3-arm
study comparing HDI (n = 215) to low-dose interferon
(LDI; 3 MU 3 times per week for 2 years, n = 215) to
observation (n = 215). HDI showed an improvement in
RFS (44% relapse-free at 5 years) compared to LDI and
observation (40% and 35%, respectively). However, unlike
ECOG trial E1684, no OS benefit was seen with either HDI
or LDI compared to observation [6]. A third study, ECOG
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Table 7: Estimated overall survival and failure-free survival probabilities at time points of interest along with corresponding 95% CIs
(n = 23).
At Time (months)
6
12
24
36

OS Probability
0.96
0.61
0.57
0.48

95% CI
0.73–0.99
0.38–0.77
0.34–0.74
0.27–0.66

FFS Probability
0.78
0.52
0.48
0.43

95% CI
0.55–0.90
0.31–0.70
0.27–0.66
0.23–0.62

Table 8: Review of retrospective literature on combination of RT and IFN α-2b for nonmelanoma.
Study

Site

Maasilta et al. [11, 12]

lung cancer n = 10

Hoﬀmann et al. [13]

lung cancer n = 6

Selman et al. [14]

lung cancer n = 38

Stevens et al. [15]

lung cancer n = 6

Verastegui et al. [16]

cervix n = 18

Rahn et al. [17]

cervix n = 4

Antonadou et al. [18]

cervix

Systemic agents
cisplatin and etoposide
combined with IFN α-2b at
3 million units IM as well
as 1.5 million units by jet
inhaler nebulizer
cis-retinoic acid with IFN
α-2b 3 million units
subcutaneous 3 times/wk
IFN α-2b 6 million
units/day for 5 days before
radiation therapy and 3
million units 4 days
afterwards
IFN α-2b 2 million units
subcutaneously 3
times/week
5 million units
subcutaneously 3
times/week of IFN α-2b
IFN α-2b, 3 million units
subcutaneously 3
times/week as well as
cis-retinoic acid
3 million units/day of IFN
α-2b and 13-cis retinoic
acid

E1694, accrued 880 patients and compared an investigational
ganglioside vaccine with HDI. HDI demonstrated a statistically significant benefit compared to the vaccine in terms of
RFS and OS [7]. This raised the question of whether HDI
led to benefit or the vaccine caused harm, a question that
has gained additional credence after a randomized trial of
the same vaccine compared to observation in patients with
stage II melanoma was stopped early because of a possible
decrease in survival for vaccine-treated patients in the face
of definite evidence of no impact on RFS [20]. With more
than 2,000 patients treated on clinical trials of adjuvant HDI,
it is clear that HDI delays recurrences and improves diseasefree survival although the magnitude of these benefits is not
optimal [21].
Multiple retrospective series have reported improvements following postoperative radiotherapy in regional
control to the resected nodal basin at high risk for subsequent

Radiation

Outcome

1.25 Gy given twice/day
to a total dose of 60 Gy

severe esophagitis
(n = 4)

50–70 Gy over 5–7 weeks

mucositis 20–50% cases

55–60 Gy

response 10/26 in those
receiving IFN α-2b with
toxicity of less fibrosis
and more pneumonitis

54–66 Gy

no appreciable benefit

extracavitary and
intracavitary radiation,
6–10 Gy

five year survival 28%
compared to 7% in the
control group; 94% of
17 patients developed
proctitis requiring
colostomy

various

25% Grade 3
desquamation and
erythema

various

“well tolerated”

failure [26–28]. These studies have consistently shown risk
factors to include multiple positive nodes (≥3 nodes),
large nodal size (≥3 cm), extracapsular extension (ECE),
and/or recurrent disease, with combinations of these factors
conferring the greatest risk. Recently, prospective data have
been reported from Australia that demonstrate improved
regional control with adjuvant radiation therapy in patients
with positive nodes, large nodes, and/or ECE [10]. This
study was presented at the 2009 annual meeting of the
American Society for Radiation Oncology as a plenary session. Inclusion criteria for this trial included any of 1 or
more parotid, 2 or more cervical or axillary, or 3 or more
positive groin nodes; ECE; at least a 3-cm node positive in
the head and neck or axilla; or a 4-cm node in the axilla.
After lymphadenectomy, patients were randomized to receive
either radiation therapy (48 Gy in 20 fractions) to the
regional nodal field or observation. Regional relapse as a first
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Table 9: Review of retrospective literature on combination of RT and IFN α-2b for melanoma.

Study

Hazard et al. [22]

Site

melanoma n = 10

Regimen

Radiation

concurrent or within 1
month

45–50 Gy

Conill et al. [23]

melanoma n = 18

concurrent or within 1
month

30 Gy/5 fractions
(n = 8), 36 Gy/6
fractions (n = 8)
50 Gy/25 fractions
(n = 2).

Gyorki et al. [24]

melanoma n = 18

concurrent

40–50 Gy in 15–25
fractions

Nguyen et al. [25]

melanoma n = 3

concurrent

41.4–66 Gy

relapse was the primary end point. Patients (n = 250; 123 in
the radiation arm and 127 in the observation arm) from 2002
to 2007 were randomized from 16 centers. Although overall
survival was not diﬀerent, this study showed a statistically
significant improvement in lymph node field control with
the addition of radiotherapy: 20 patients in the radiation
arm versus 34 patients in the observation arm (P = 0.041)
[10]. Although these emerging data help confirm the role
of radiotherapy in the adjuvant setting, integration with
systemic treatment has never been prospectively tested until
this study.
There is little published retrospective experience with
concurrent radiation and IFN α-2b. Radiation has been given
together with IFN α-2b in a limited number of patients
with carcinoma of the lung and cervix [11–18]. A summary
of these studies is described in Table 8. Several small
retrospective studies have recently been reported on the role
of concurrent radiotherapy or interferon or radiotherapy
within 1 month of the delivery of interferon in resected
high-risk melanoma [22–25]. These studies have generally
reported locoregional control rates to be comparable with
historical rates (Table 9). However, despite small numbers of
patients in these series, there has been concern over greater
than expected late toxicity particularly soft tissue injury, lung
injury, and myelitis.
Thus, in 1997 we established a prospective long-term trial
of these combination of agents with careful monitoring of
acute and late toxicity over >10 years with the belief that if
long-term toxicity could be found to be acceptable, this treatment program could be then tested in a larger randomized

Outcome
5/10 severe subacute/late
complications including two
patients with peripheral
neuropathy, one patient with
radiation necrosis in the brain,
and two patients with radiation
necrosis in the subcutaneous
tissue.
FFS at 3 years was 88%. All the
patients experienced grade I
acute skin reactions. Late toxicity
was seen in one patient with
grade III (RTOG) skin reaction
and two with grade IV (RTOG)
radiation-induced myelitis.
7/18 grade 3 skin reactions.
Severe radiation-induced toxicity
was seen in three patients, one
who developed radiation
pneumonitis, one who developed
severe oral mucositis, and one
who developed wound
dehiscence.
All three patients achieved local
control at 24, 18 and 19 months
followup; one patient developed
widespread distant metastases.

trial to document eﬃcacy. Although our target accrual goal
was 50 patients, we were only able to enroll 29 patients. A
significant reason included diﬃculties in enrolling patients as
cooperative group data emerged showing less clear benefits
in overall survival with the use of interferon. Additionally
there was increasing concern amongst some investigators
over possible late eﬀects.
Our data suggest that the number of patients experiencing high-grade (Gr 3-4) interferon hematologic and nonhematologic toxicity reported during any phase of therapy
is comparable with prior experience. What is remarkable is
that the maximum (worst) grade of acute radiation toxicity
during concurrent RT/IFN (and up to 2 weeks post RT)
was quite low with grade 3 skin toxicity noted in 2 patients
(9%). In addition, at the median follow-up of more than 6
years among ten survivors, no patient experienced a grade
3 toxicity. Only one patient developed a grade 4 toxicity
following 3 cycles of bio-chemotherapy for recurrence in
axilla. Finally, grade 1 and 2 late radiation toxicities following
concurrent RT/IFN were minimal including skin telangiectasia, subcutaneous fibrosis, limitation in joint motion, and
lymphedema.
Despite these promising results, we no longer use this
particular radiation fractionation schedule at our center
due to concerns regarding potential late eﬀects associated
with large dose per fraction radiotherapy. Although the
observed rate of late eﬀects was acceptable, the power to
detect true rates of late injuries is small in this pilot study.
We now routinely use intensity-modulated radiation therapy
(IMRT) for complex axillary and groin targets to improve
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homogeneity and to reduce the volume of normal tissue at
risk for fibrosis or other injury.
[11]

5. Summary
In summary, these data suggest that post-operative concurrent hypofractionated RT and IFN for advanced stage
III melanoma are associated with acceptable acute and
late toxicity and provide reasonable in-field control in
patients at high risk of regional failure. These data may
be useful in advancing new concurrent radiation and bioimmunotherapy trials [29–32].

[12]

[13]

Disclosure
V. Sondak is a consultant for Merck/Schering-Plough. This
paper presented in oral form at 50th Annual ASTRO Meeting, Boston, Massachusetts, and ASTRO Head and Neck
Symposium, Chandler, Arizona.
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